We are a Swiss microbiome biotherapeutics company with two key platforms:

1. ApyraVax with the lead indication of Clostridioides difficile infection
2. ApyraMed with lead indications as Cancer Immunotherapy Enhancer and Dysbiosis

 

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2015
  • Number of employees in Switzerland
    1-9
Key business